Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gentian Diagnostics ASOSL:GENT +5.24%73 ROC (Joel Greenblatt) % is 32.68% as of Jun. 2026. GuruFocus rates OSL:GENT with a GF Score™ of 73/100 and a GF Value™ of kr59.20 (Significantly Undervalued). Among 840 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks worse than 53.57% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Gentian Diagnostics AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 32.68%.
The historical rank and industry rank for Gentian Diagnostics AS's ROC (Joel Greenblatt) % or its related term are showing as below:
OSL:GENT'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -152.73 Med: -59.11 Max: 43.69
Current: 0.44
During the past 13 years, Gentian Diagnostics AS's highest ROC (Joel Greenblatt) % was 43.69%. The lowest was -152.73%. And the median was -59.11%.
OSL:GENT's ROC (Joel Greenblatt) % is ranked worse than 53.57% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.145
vs OSL:GENT: 0.44
Gentian Diagnostics AS's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Gentian Diagnostics AS (OSL:GENT) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Gentian Diagnostics AS ROC (Joel Greenblatt) % Related Terms
Gentian Diagnostics AS ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Gentian Diagnostics AS's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS ROC (Joel Greenblatt) % Chart
OSL:GENT vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's ROC (Joel Greenblatt) % falls into.
Gentian Diagnostics AS ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 32.68% mean?
Gentian Diagnostics AS (OSL:GENT) has a ROC (Joel Greenblatt) % of 32.68% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Gentian Diagnostics AS and its competitors. According to the industry distribution chart, Gentian Diagnostics AS ranks #450 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 53.6%.
Is Gentian Diagnostics AS's ROC (Joel Greenblatt) % too high?
Gentian Diagnostics AS's current ROC (Joel Greenblatt) % is 32.68%. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.15. Gentian Diagnostics AS's value of 32.68% is 688.4% above this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #450 out of 840 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #450 out of 840 companies for ROC (Joel Greenblatt) %. This places Gentian Diagnostics AS in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.15. Gentian Diagnostics AS's value of 32.68% is 688.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current ROC (Joel Greenblatt) % of 32.68% is 688.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current ROC (Joel Greenblatt) % is 32.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr59.20, compared to a current price of kr40.20 — trading 32.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is 32.68% and 688.4% above the Medical Devices & Instruments industry median of 4.15. Gentian Diagnostics AS's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current ROC (Joel Greenblatt) % is 32.68% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr40.20 is trading 32.1% below its estimated GF Value™ of kr59.20.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for OSL:GENT:
ROC (Joel Greenblatt) %: 32.68%
GF Value™: kr59.20 vs. price of kr40.20 (32.1% below fair value)
Industry Position: 688.4% above the Medical Devices & Instruments median (#450 of 840)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
73GF Score
Get the complete analysis for OSL:GENT
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
